Approval · Notice of Compliance 1017 · 2003
ZOLADEX: Notice of Compliance 1017
Issued March 19, 2003
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 1017
- Date
- March 19, 2003
- Company
- Astrazeneca Canada IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New indication: adjuvant therapy in pre- and perimenopausal women with early breast cancer, whose tumour contains estrogen and/or progesterone receptors
- Therapeutic class
- Luteinizing hormone - releasing hormone (lhrh) analog
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ZOLADEX | Not yet assigned | — |
Medicinal ingredients
- GOSERELIN ACETATE 3.6 MG per DOSE